Agomab Therapeutics NV Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
David R Epstein, a Director of Agomab Therapeutics NV, purchased 10,000 shares of common stock on October 21, 2026.
NASDAQ
David R Epstein, a Director of Agomab Therapeutics NV, purchased 5,000 shares of common stock on October 8, 2026 for $8.90 per share.
NASDAQ
David R Epstein, a Director of Agomab Therapeutics NV, purchased 10,000 shares of common stock on October 5, 2026.
NASDAQ
Pierre Thadee Victor Kemula, Chief Financial Officer of Agomab Therapeutics NV, purchased 10,000 shares of common stock on October 6, 2026.
NASDAQ
Tim Jasper Knotnerus, Chief Executive Officer and a Director of Agomab Therapeutics NV, purchased 11,000 shares of common stock on October 5, 2026.
NASDAQ
Marino Garcia, a Director of Agomab Therapeutics NV, received 57,482 shares of common stock on September 11, 2026.
NASDAQ
Naimish Patel, a Director of Agomab Therapeutics NV, received 56,328 shares of common stock on September 11, 2026.